You are here: Industry Insights > Owlstone Medical

News List

Owlstone Medical’s breath biopsy test improves detection of liver disease pharmatimes
September 27, 2020
Cambridge-based Owlstone Medical has announced new results from a study of its breath-based diagnostic test for liver disease, including Nonalcoholic Fatty Liver Disease (NAFLD) and associated Nonalcoholic steatohepatitis (NASH).
Owlstone Medical explores breath-based testing for more diseases pharmatimes
June 18, 2019
Owlstone Medical has announced that it’s investigating a novel approach to breath-based testing for the onset, progression, and treatment of various diseases.
Owlstone Medical, Actelion team up for pulmonary hypertension detection pharmatimes
May 20, 2019
Owlstone Medical has announced a strategic partnership with Actelion Pharmaceuticals.
Owlstone Medical Raises $15 Million USD (£11 million GBP) To Drive Commercialization of Its Breath B biospace
March 06, 2018
Owlstone Medical Ltd., a diagnostics company developing a breathalyzer for disease, announced today that it has raised $15 million (£11 million) to drive the global commercialization of its Breath Biopsy® platform.